CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Inactive · Last trade price on Jun 23, 2023

CTI BioPharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 2017 - 2013
Revenue
75.7753.95003.3526.29
Upgrade
Revenue Growth (YoY)
3201.48%----87.28%4.55%
Upgrade
Cost of Revenue
4.463.510000
Upgrade
Gross Profit
71.3150.43003.3526.29
Upgrade
Selling, General & Admin
88.6984.8356.217.6319.1622.06
Upgrade
Research & Development
39.0636.939.1425.9424.1136.47
Upgrade
Other Operating Expenses
-2.518.5104.20.790.66
Upgrade
Operating Expenses
125.24130.2395.3347.7744.0659.19
Upgrade
Operating Income
-53.93-79.8-95.33-47.77-40.71-32.9
Upgrade
Interest Expense / Income
15.2613.142.420.8311.21
Upgrade
Other Expense / Income
0.050.060.163.85-1.69-4.79
Upgrade
Pretax Income
-69.24-92.99-97.91-52.45-40.02-29.32
Upgrade
Net Income
-69.24-92.99-97.91-52.45-40.02-29.32
Upgrade
Preferred Dividends
000000.08
Upgrade
Net Income Common
-69.24-92.99-97.91-52.45-40.02-29.4
Upgrade
Shares Outstanding (Basic)
13211590715856
Upgrade
Shares Outstanding (Diluted)
13211590715856
Upgrade
Shares Change
31.78%27.27%26.67%22.71%3.39%53.86%
Upgrade
EPS (Basic)
-0.56-0.81-1.09-0.74-0.69-0.52
Upgrade
EPS (Diluted)
-0.56-0.81-1.09-0.74-0.69-0.52
Upgrade
Free Cash Flow
-82.32-81.19-84.89-42.22-27.82-39.86
Upgrade
Free Cash Flow Per Share
-0.63-0.71-0.94-0.59-0.48-0.71
Upgrade
Gross Margin
94.11%93.49%--100.00%100.00%
Upgrade
Operating Margin
-71.18%-147.91%---1217.07%-125.14%
Upgrade
Profit Margin
-91.38%-172.37%---1196.41%-111.83%
Upgrade
Free Cash Flow Margin
-108.64%-150.50%---831.75%-151.61%
Upgrade
EBITDA
-51.83-77.9-94.97-51.09-38.47-27.52
Upgrade
EBITDA Margin
-68.40%-144.40%---1150.13%-104.67%
Upgrade
Depreciation & Amortization
2.151.950.530.530.550.59
Upgrade
EBIT
-53.98-79.85-95.49-51.62-39.02-28.11
Upgrade
EBIT Margin
-71.24%-148.02%---1166.46%-106.93%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).